866-997-4948(US-Canada Toll Free)

Diabetic Neuropathy - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 75 Pages


Global Markets Directs, \'Diabetic Neuropathy Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Diabetic Neuropathy Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Neuropathy.
  • A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Neuropathy Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diabetic Neuropathy 9
Diabetic Neuropathy Therapeutics under Development by Companies 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Diabetic Neuropathy Therapeutics - Products under Development by Companies 16
Companies Involved in Diabetic Neuropathy Therapeutics Development 17
Merck & Co., Inc. 17
Dainippon Sumitomo Pharma Co., Ltd. 18
Takeda Pharmaceutical Company Limited 19
Dong-A Pharmaceutical Co., Ltd. 20
Neuralstem, Inc. 21
Lpath, Inc. 22
DiaMedica Inc. 23
R-Tech Ueno, Ltd. 24
Neurotune AG 25
Intellect Neurosciences, Inc. 26
Glucox Biotech 27
Vascular Pharmaceuticals, Inc. 28
TheraQuest Biosciences, LLC 29
Diabetic Neuropathy - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ranirestat - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TAK-428 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Lpathomab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NT-13317 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RTU-1096 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
INN-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
DA-3030 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
filorexant - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GLY-230 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NSI-566 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
mepivacaine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NT-24336 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DA-9801 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ARA-290 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drug For Diabetic Neuropathy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Stem Cell Therapy For Diabetic Complications - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VPI-2690-B - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drug For Diabetic Neuropathy And Retinopathy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DM-433 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Diabetic Neuropathy Therapeutics - Drug Profile Updates 58
Diabetic Neuropathy Therapeutics - Discontinued Products 67
Diabetic Neuropathy Therapeutics - Dormant Products 68
Diabetic Neuropathy - Product Development Milestones 69
Featured News & Press Releases 69
Mar 28, 2013: NeuroMax Receives Permission To Conduct Phase Ib Clinical Trial Of NM-IA-001 For Treatment Of Diabetic Polyneuropathy 69
Jan 30, 2013: NeuroMax Successfully Completes Phase Ia Clinical Trials Of NM-IA-001 In Patients With Diabetic Neuropathy 69
Nov 27, 2012: ChemoCentryx Announces Initiation Of Phase I Clinical Trial Of CCX872 70
Oct 15, 2012: Genkyotex Announces Presentation Of Data From Phase I Studies Of GKT137831 At Kidney Week 2012 70
May 10, 2012: NeuroMax Receives Authorization To Conduct Clinical Trials With NM-IA-001 In Russia 70
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 71
Nov 07, 2011: NephroGenex Reaches Agreement With FDA On Subpart H Phase III Program For Pyridorin 71
Oct 31, 2011: J&JPRD Submits Supplemental New Drug Application To FDA For NUCYNTA ER Tablets For Diabetic Peripheral Neuropathic Pain 72
Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting 72
Oct 18, 2011: NeuroMax Announces Positive Preclinical Trial Results Of NM-IA-001 In Diabetic Neuropathy 73

Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Table


Number of Products Under Development for Diabetic Neuropathy, H2 2013 9
Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Merck & Co., Inc., H2 2013 17
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 18
Takeda Pharmaceutical Company Limited, H2 2013 19
Dong-A Pharmaceutical Co., Ltd., H2 2013 20
Neuralstem, Inc., H2 2013 21
Lpath, Inc., H2 2013 22
DiaMedica Inc., H2 2013 23
R-Tech Ueno, Ltd., H2 2013 24
Neurotune AG, H2 2013 25
Intellect Neurosciences, Inc., H2 2013 26
Glucox Biotech, H2 2013 27
Vascular Pharmaceuticals, Inc., H2 2013 28
TheraQuest Biosciences, LLC, H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 34
Diabetic Neuropathy Therapeutics - Drug Profile Updates 58
Diabetic Neuropathy Therapeutics - Discontinued Products 67
Diabetic Neuropathy Therapeutics - Dormant Products 68

List of Chart


Number of Products under Development for Diabetic Neuropathy, H2 2013 9
Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Discovery and Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 30
Assessment by Route of Administration, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Molecule Type, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *